-
EP3661501
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3661501
| EP3661501 - USE OF MAVOGLURANT IN THE REDUCTION OF ALCOHOL USE OR IN PREVENTING RELAPSE INTO ALCOHOL USE [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 02.04.2022 Database last updated on 20.07.2024 | |
| Former | Request for examination was made Status updated on 08.05.2020 | ||
| Former | The international publication has been made Status updated on 09.02.2019 | ||
| Former | unknown Status updated on 07.09.2018 | Most recent event Tooltip | 22.12.2023 | New entry: Reply to examination report | Applicant(s) | For all designated states Novartis AG Lichtstrasse 35 4056 Basel / CH | [2020/24] | Inventor(s) | 01 /
DOLMETSCH, Ricardo Novartis Institutes for BioMedical Research Inc. 250 Massachusetts Avenue Cambridge, Maryland 02139 / US | 02 /
GASPARINI, Fabrizio Novartis Pharma AG Postfach 4002 Basel / CH | 03 /
JOHNS, Donald Novartis Institutes for BioMedical Research Inc. 250 Massachusetts Avenue Cambridge, Massachusetts 02139 / US | 04 /
GOMEZ-MANCILLA, Baltazar Novartis Pharma AG Postfach 4002 Basel / CH | [2020/24] | Representative(s) | Stolmár & Partner Intellectual Property GmbH Bahnhofstrasse 106 8001 Zürich / CH | [N/P] |
| Former [2020/24] | Gabarda Ortega, Ana Esther Novartis Pharma AG Patent Department 4002 Basel / CH | Application number, filing date | 18759744.8 | 30.07.2018 | [2020/24] | WO2018IB55665 | Priority number, date | US201762539008P | 31.07.2017 Original published format: US 201762539008 P | [2020/24] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019025932 | Date: | 07.02.2019 | Language: | EN | [2019/06] | Type: | A1 Application with search report | No.: | EP3661501 | Date: | 10.06.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 07.02.2019 takes the place of the publication of the European patent application. | [2020/24] | Search report(s) | International search report - published on: | EP | 07.02.2019 | Classification | IPC: | A61K31/404, A61K45/06, A61P25/32 | [2020/24] | CPC: |
A61K45/06 (EP,KR,US);
A61K31/404 (EP,KR);
A61K31/403 (US);
A61P25/32 (EP,KR,US);
A61K2300/00 (KR)
| C-Set: |
A61K31/404, A61K2300/00 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/24] | Title | German: | VERWENDUNG VON MAVOGLURANT ZUR VERMINDERUNG DES ALKOHOLKONSUMS ODER ZUR VERHINDERUNG EINES ALKOHOLKONSUMRÜCKFALLS | [2020/24] | English: | USE OF MAVOGLURANT IN THE REDUCTION OF ALCOHOL USE OR IN PREVENTING RELAPSE INTO ALCOHOL USE | [2020/24] | French: | UTILISATION DE MAVOGLURANT DANS LA RÉDUCTION DE L'UTILISATION D'ALCOOL OU DANS LA PRÉVENTION DE RECHUTE DANS L'UTILISATION D'ALCOOL | [2020/24] | Entry into regional phase | 02.03.2020 | National basic fee paid | 02.03.2020 | Designation fee(s) paid | 02.03.2020 | Examination fee paid | Examination procedure | 02.03.2020 | Examination requested [2020/24] | 02.03.2020 | Date on which the examining division has become responsible | 09.09.2020 | Amendment by applicant (claims and/or description) | 01.04.2022 | Despatch of a communication from the examining division (Time limit: M06) | 30.09.2022 | Reply to a communication from the examining division | 29.06.2023 | Despatch of a communication from the examining division (Time limit: M06) | 21.12.2023 | Reply to a communication from the examining division | Fees paid | Renewal fee | 14.07.2020 | Renewal fee patent year 03 | 15.07.2021 | Renewal fee patent year 04 | 28.06.2022 | Renewal fee patent year 05 | 31.07.2023 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]US8703809 (GOMEZ-MANCILLA BALTAZAR [CH], et al) [X] 16 * claim 1 *; | [X]WO2015197079 (CONTERA PHARMA APS [DK]) [X] 16 * claims 1, 21, 25, 49 *; | [XY]US2016128979 (THOMA HUBERT [DE], et al) [X] 1,3,5,13-15 * abstract * * paragraphs [0029] , [ 0069] - [0072] * [Y] 1-15; | [Y] - M. F. OLIVE ET AL, "The mGluR5 Antagonist 6-Methyl-2-(phenylethynyl)pyridine Decreases Ethanol Consumption via a Protein Kinase C -Dependent Mechanism", MOLECULAR PHARMACOLOGY, US, (20050201), vol. 67, no. 2, doi:10.1124/mol.104.003319, ISSN 0026-895X, pages 349 - 355, XP055518663 [Y] 1-15 * abstract * DOI: http://dx.doi.org/10.1124/mol.104.003319 | by applicant | WO03047581 | WO2010018154 | WO2014199316 | - Alcohol Clin Exp Res, (20160000), vol. 40, no. 7, pages 1368 - 1379 | - Addiction, (20060000), vol. 101, pages 212 - 222 | - Alcohol Clin Exp Res, (19960000), vol. 20, pages 16 - 20 | - SHARKO, A. C. et al., Soc. Neurosci. Abstr., (20020000), vol. 783.781 | - OLIVE, M. F. et al., Mol. Pharmacol., (20050000), vol. 67, pages 349 - 3550 | - KECK et al., Psychopharmacology, (20130000), vol. 229, no. 2, pages 253 - 65 | - SMITH et al., Bioorg Med Chem Lett, (20040000), vol. 14, pages 5481 - 5484 | - COSFORD et al., J. Med. Chem., (20030000), vol. 46, no. 2, pages 204 - 206 | - O'LEARY et al., Br J Pharmacol, (20000000), vol. 131, pages 1429 - 1437 | - HEIDBREDER et al., Synapse, (20030000), vol. 50, pages 269 - 276 | - LEA; FADEN, CNS Drug Rev, (20060000), vol. 12, pages 149 - 166 | - J. Anal. Toxicolo., (20020000), vol. 26, pages 393 - 400 | - BECK, A.T. et al., "An inventory for measuring depression", Archives of General Psychiatry, (19610000), vol. 4, pages 561 - 571 | - BECK, A. T. et al., "Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation", Clinical Psychology Review, (19880000), vol. 8, no. 1, pages 77 - 100 | - Psychiatry, (20070000), vol. 4, no. 7, pages 28 - 37 | - J. Anal. Toxicolo, (20020000), vol. 26, pages 393 - 400 | - "International Guide for Monitoring Alcohol Consumption and Related Harm", World Health Organization, (20000000), page 51, URL: http://www.who.int/iris/handle/10665/66529 | - MOELLER FG, Am J Psychiatry., (20010000), vol. 158, pages 1783 - 1793 | - NIAAA, Project MATCH Monograph Series, NIH, (19950000), vol. 1 | - Arch. Gen. Psychiatry, (19990000), vol. 56, pages 493 - 502 | - Psychol Addict Behav, (20090000), vol. 23, no. 1, pages 168 - 174 | - J. Consul. Clin. Psychol., (20050000), vol. 73, no. 2, pages 354 - 59 | - Case Reports in Psychiatry, vol. 2012 | - Drug Alcohol Depend, (20040000), vol. 74, pages 1 - 13 | - J. Consul. Clin. Psychol., (20010000), vol. 69, no. 5, pages 858 - 62 | - Drug Alcohol Depend, (20070000), vol. 91, pages 97 - 101 | - Addiction, (20040000), vol. 99, no. 7, pages 862 - 874 | - J. Consul. Clin. Psychol., (20000000), vol. 68, no. 3, pages 515 - 52 | - Remington's Pharmaceutical Sciences, Mack Printing Company, (20130000), pages 1049 - 1070 | - Diagnostic and Statistical Manual of Mental Disorders | - Glutamate-based therapies for psychiatric disorders, Springer, (20000000), pages 133 - 147 | - CHIAMULERA, C., Nat. Neurosci., (20010000), vol. 4, pages 873 - 874 | - KENNY, P. J. et al., Behav. Pharmacol., vol. 14, page S55 | - MARTIN-FARDON R. et al., J. Pharmacol Exp Ther, (20090000), vol. 329, no. 3, page 1084 |